Beth Gaston Moon

Beth Gaston Moon

With more than a decade of experience as a financial journalist and market analyst, Beth Gaston Moon writes about stocks and options from her home in Chicago, IL.

Beth began her derivatives-market career in the research department of Cincinnati-based newsletter publisher Schaeffer’s Investment Research. She started by copy-editing The Options Advisor (the nation’s leading options newsletter) and soon began writing daily market commentaries for SchaeffersResearch.com.

After more than a decade with Schaeffer’s, Beth served as senior editor for PEAK6 Media, composing scripts, trading ideas and articles for The Options News Network. Most recently, she was the senior content and product manager for retail brokerage OptionsHouse.

In 2004, Beth was recognized as a “Woman in Finance” by Money Show Digest. Her market comments have appeared in several media outlets, including Dow Jones Newswires, CBS MarketWatch, Money Show Digest and Reuters. She has also been a contributing author for Forbes.com and Active Trader and Stocks, Futures & Options magazines.

Recent Articles

Is It Finally Time to Sell Sears?

Sears has multiple strikes against a continued uptrend. Here's why it might be time to bow out of SHLD.

Options Buyers Lick Their Chops Ahead of ‘Hunger Games’ Opening

Option bulls expect big box-office receipts to lift Lion’s Gate shares.

4 Reasons Why Wendy’s Will Never Top McDonald’s

Wendy’s ekes past Burger King to take the No. 2 spot -- but it’s a hollow victory. It can never go beyond that.

Options Volume Spikes on High-Fashion Names

Options traders are bullish on Michael Kors, but bearish on Ralph Lauren. Both saw unusually heavy action on Monday.

Target Aggressively Targets a Dividend Hike

Flush with cash -- and with a solid history of raising dividends, Target says it's aiming to pay a $3 annual dividend by 2017.

Staples Bulls See Long-Term Upside

Option players buy long-dated call options in hopes of a prolonged rally in Staples shares.

Why Investors Needn’t Fear the ‘Patent Cliff’

Expiring drug patents can cost pharma stocks billions of dollars, but companies and investors alike can prepare themselves well in advance.

What Apple’s Charts May Be Telling Us

Apple's ascent leaves even most technical analysis gasping. Its very high RSI might hint at near-term consolidation, but that's hardly a sure thing.

Office Depot Options Activity Spikes

Option traders bet on Office Depot’s long-term upside potential, with unusually heavy volumes of long calls and long straddles.

Overall Retail Sales Hit New Record

Retailing performed across the board in February, slightly exceeding analysts’ estimates, with vehicle and apparel sales particularly strong.